rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

Overview

The trials in this protocol deals with the effect of pretreatment with rhTSH on radioiodine treatment of thyroid size and function, in patients with nontoxic and toxic nodular goiter. It is an introduction of a novel principle, based on prospective, randomized double blind investigations. Attached to this, we investigate the acute effects of rhTSH on thyroid size (measured by ultrasonography), both in healthy individuals and in patients with nontoxic nodular goiter. Thus, the investigations are divided into 4 categories listed below: 1. Prospective randomized double blind study of pretreatment with 0.3 mg recombinant human TSH for the effect of radioiodine in nontoxic multinodular goiter. 2. Prospective randomized double blind study of the pretreatment with 0.3 mg recombinant human TSH for the effect of radioiodine on thyroid size and function in patients with a very large (>100 ml) nontoxic or toxic goiter. 3. Does administration of 0.9 mg recombinant human TSH affect thyroid function and volume in healthy individuals? A randomized double-blind cross-over trial. 4. Does administration of 0.3 mg recombinant human TSH affect thyroid function and volume in healthy individuals and in patients with multinodular non-toxic goiter? A randomized double-blind cross-over trial. As a final note we investigate, in a pilot-study; 5. The influence of rhTSH on thyroid radioiodine uptake in patients with hyperthyroidism treated with continuous block-replacement therapy.

Full Title of Study: “Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double

Interventions

  • Drug: Recombinant human thyrotropin (Thyrogen)

Clinical Trial Outcome Measures

Primary Measures

  • Ultrasonography/MR of the thyroid gland/benign goiter, in order to determine thyroid size after intervention.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy volunteers with an intact thyroid gland – Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography – Patients with toxic nodular goiter – Patients with Graves' disease Exclusion Criteria:

  • Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion) – Prior 131I treatment – Alcohol, medicine or drug abuse – Pregnancy or lactation – No safe contraception – Participation in another clinical trial – Allergic reaction towards rhTSH – Fine needle biopsy without valid diagnostic criteria for benign disease – Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin – Incontinence – Physically or psychic condition that hinders corporation – Ischemic attack up till 3 months before inclusion

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Odense University Hospital
  • Overall Official(s)
    • Viveque Egsgaard Nielsen, MD, Principal Investigator, Odense University Hospital

Citations Reporting on Results

Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med. 2006 Jul 24;166(14):1476-82. doi: 10.1001/archinte.166.14.1476.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.